trending Market Intelligence /marketintelligence/en/news-insights/trending/pnkn7z1tpoqzeonl5lvvwa2 content esgSubNav
In This List

Roche's Tecentriq combo meets main goals in late stage lung cancer study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Roche's Tecentriq combo meets main goals in late stage lung cancer study

Roche Holding AG said a late stage study of Tecentriq plus chemotherapy met its main goals, helping people with a type of lung cancer live significantly longer compared to chemotherapy alone.

Results from the phase 3 trial, dubbed IMpower130, showed Tecentriq, also known as atezolizumab, combined with chemotherapy drugs carboplatin — sold by Bristol-Myers Squibb Co. as Paraplatin — and Celgene Corp.'s Abraxane, helped prolong lives compared to chemotherapy alone in the initial treatment of advanced, non-squamous non-small cell lung cancer, or NSCLC.

SNL Image

The combination treatment also reduced the risk of disease worsening or death, compared to chemotherapy alone.

The Swiss drugmaker said safety for Tecentriq with chemotherapy was consistent with the known safety profile of the individual medicines. There were no new safety signals identified with the combination.

Tecentriq is already approved in the EU, the U.S. and more than 70 countries for people with previously treated metastatic NSCLC — lung cancer that has spread that has spread from the original site to another site in the body — and for certain people with locally advanced or metastatic urothelial cancer.